Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Catalyst Pharmaceuticals excels in 2022, eyes sustained growth in epilepsy market

Catalyst Pharmaceuticals delivered exceptional financial performance in 2022, with strong revenue growth and strategic acquisitions positioning the company for continued success.
While facing challenges in maintaining sequential quarterly revenue growth, Catalyst's focus on innovation, patient care, and financial stability presents opportunities for sustained growth.
Overall, Catalyst's industry leadership, financial strength, and commitment to expanding product access and market presence underscore its potential for future growth and success.

Catalyst Pharmaceuticals reports record Q1 earnings, eyes growth opportunities

Catalyst Pharmaceuticals delivered exceptional financial results in Q1 2023, with strong revenue growth and a healthy cash position, positioning the company for continued success.
While facing challenges such as seasonal sales trends and diagnosis rates, the company's strategic focus on acquisitions and market expansion presents promising opportunities for future growth.
With a clear commitment to organic growth, product integration, and market penetration, Catalyst Pharmaceuticals remains poised for sustained performance and market leadership.

Catalyst Pharmaceuticals excels in Q2, eyes global expansion and new treatments

Catalyst Pharmaceuticals delivered strong financial performance in Q2 2023, driven by revenue growth and strategic initiatives.
While facing challenges in patient identification and treatment, the company remains focused on expansion and innovation in rare disease therapeutics.
Opportunities lie in upcoming product launches, global expansion, and collaboration efforts to drive future growth and market penetration.

Catalyst Pharmaceuticals (CPRX) excels in Q3, eyes global expansion

Catalyst Pharmaceuticals (CPRX) demonstrated robust financial performance in Q3 2023, driven by strong product revenues and strategic initiatives.
While facing challenges in managing launch expenses and regulatory processes, CPRX remains focused on leveraging growth opportunities through global expansion and portfolio enhancements.
With a new CEO appointment and a clear focus on market expansion and innovation, CPRX is poised for sustained growth and value creation in the pharmaceutical sector.

Catalyst Pharmaceuticals posts record revenues, eyes growth in rare diseases

Catalyst Pharmaceuticals delivered strong financial performance in 2023, driven by record revenues and strategic acquisitions.
While facing challenges with FYCOMPA's growth and upcoming patent expiry, the company remains well-positioned for growth in rare disease markets.
Opportunities lie in the launch of AGAMREE, expansion into new therapeutic areas, and leveraging the stickiness of epilepsy drugs post-patent expiry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company was founded by Hubert E. Huckel and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

Catalyst Pharmaceutical (CPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Catalyst (CPRX) Up 8.9% Since Last Earnings Report: Can It Continue?

Genmab - ADR

Harmony Biosciences Holdings

Neurocrine Biosciences

Top biotech stocks surge within the IBD 50. Some pass buy points while others build bases.

Hot Biotech Stocks Rise Into Leadership; Pass Buy Points Or Build Bases

Catalyst Pharmaceuticals is in the process of entering new markets for its drug, Firdapse. It's also generating plenty of cash to spend on generating more growth.

Catalyst Pharmaceuticals: Undervalued And Likely To Outperform

Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?

Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.

Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Ali Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Jeffrey Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Les Sulewski - Truist Scott Henry - ROTH Capital Operator Good day, ladies and gentlemen and welcome to the Catalyst Pharmaceuticals Incorporated Third Quarter 2022 Financial Results Conference Call. All lines have been placed on a listen-only mode, and the floor will be open for questions and comments following the presentation.

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2022 Earnings Call Transcript

Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase

Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update

On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.

Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?

CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it has been named the “2022 David J. Gury Company of the Year” by BioFlorida. The award recognizes one company that accomplishes significant milestones and achievements leading to the advancement of life sciences in Florida.

Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year

Catalyst Pharmaceuticals approaches a buy point with earnings due. Stellar ratings support the price action.

Biotech Stock Catalyst Pharmaceuticals Offers Buy Point Ahead Of Earnings

Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022

Corcept Therapeutics

Vertex Pharmaceuticals

Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.

These 3 Stocks Are Winning the Bear Market -- Here's How

Aerie Pharmaceuticals

Fusion Pharmaceuticals

Jazz Pharmaceuticals

Larimar Therapeutics Inc

Innovation is expected continue driving growth in the Medical-Drugs industry in 2023. JAZZ, CPRX, AERI, LRMR and FUSN may prove to be good additions to one's portfolio.

5 Stocks to Bet on in an Innovation-Driven Drug Industry

Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.

Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

Cardinal Health

DoubleVerify Holdings

Cheniere Energy

Paylocity Hlds

Shockwave Medical

Wolfspeed

As the market indexes work through a downturn, Vertex is among eight stocks to watch showing relative strength. The post Vertex Among 8 Stocks To Watch In Struggling Market appeared first on Investor's Business Daily.

Vertex Among 8 Stocks To Watch In Struggling Market

Here is how Catalyst Pharmaceutical (CPRX) and IMARA Inc. (IMRA) have performed compared to their sector so far this year.

Is Catalyst Pharmaceuticals (CPRX) Stock Outpacing Its Medical Peers This Year?

Catalyst Pharmaceuticals (CPRX) announces FDA approval of its sNDA for Firdapse to include pediatric patients for treating Lambert-Eaton myasthenic syndrome.

Catalyst Pharma's (CPRX) sNDA for Firdapse Approved by the FDA

FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. FIRDAPSE is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S.

Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients

COMPASS Pathways

Their low price tags belie their massive long-term potential.

2 No-Brainer Stocks to Buy Right Now for Less Than $15

Belite Bio Inc

Chemocentryx

Verona Pharma

Akero Therapeutics Inc

Gossamer Bio Inc

Relmada Therapeutics Inc

Viridian Therapeutics

Ventyx Biosciences

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

Looking for a Growth Stock? 3 Reasons Why Catalyst (CPRX) is a Solid Choice

Catalyst (CPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Catalyst (CPRX) Upgraded to Buy: Here's What You Should Know

BioMarin Pharmaceutical

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

News for Catalyst Pharmaceuticals Stock (CPRX)